WILLIAM CHAMBERLAIN: Open Payments
NPI 1760857247 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$241 in 14 payments from 10 companies in 2025. Trend: 2023 $133 · 2024 $644 · 2025 $241
Food & beverage: $241
| Company | Payments | Amount |
|---|---|---|
| Antares Pharma, Inc. | 4 | $84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $27 |
| Saluda Medical Americas, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| ABBVIE INC. | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
| Novo Nordisk Inc | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
Products named: XYOSTED, JARDIANCE, Evoke, MOUNJARO, Tlando, LINZESS, Kerendia, FARXIGA.
Industry payments across CA — which companies pay providers there.
